Piling on, ABMD

Not enough bad news, I guess.

Abbott Labs purchased St. Jude.


The combination is #1 or #2 in all areas of cardiovascular. Well, maybe the ABMD head-to-head will get lost in a larger Abbott. One can only hope. ABMD down 1.27% (hardly noticeable with INFN rout).


1 Like